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Background: Glycogen phosphorylases catalyze the breakdown of glycogen to
glucose-1-phosphate for glycolysis. Maintaining control of blood glucose levels is
critical in minimizing the debilitating effects of diabetes, making liver glycogen
phosphorylase a potential therapeutic target.
Results: The binding site in human liver glycogen phosphorylase (HLGP) for a
class of promising antidiabetic agents was identi¢ed crystallographically. The site
is novel and functions allosterically by stabilizing the inactive conformation of
HLGP. The initial view of the complex revealed key structural information and
inspired the design of a new class of inhibitors which bind with nanomolar af¢nity
and whose crystal structure is also described.
Conclusions: We have identi¢ed the binding site of a new class of allosteric
HLGP inhibitors. The crystal structure revealed the details of inhibitor binding, led
to the design of a new class of compounds, and should accelerate efforts to
develop therapeutically relevant molecules for the treatment of diabetes.
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Introduction
Non-insulin-dependent (type 2) diabetes mellitus is a dis-
ease characterized by high levels of glucose in the plasma
and leads to complications such as nerve and kidney dam-
age, blindness, premature atherosclerosis and heart disease.
In the United States, 15.6 million people have been diag-
nosed with type 2 diabetes [1]. The molecular basis of the
disease remains poorly understood but is characterized by
peripheral insulin resistance and pancreatic defects in in-
sulin secretion. Intensive control of blood glucose levels
prevents and delays the onset of diabetic complications
[2] but such control is rarely achieved with oral antidiabetic
agents. Liver phosphorylase catalyzes glycogenolysis (the
phosphorolysis of an K (1-4) glycosidic bond in glycogen to
yield glucose-1-phosphate for metabolism) and plays an
important role in hepatic glucose production. In diabetic
subjects, glycogenolysis remains an important contributor
to hepatic glucose output even when blood glucose levels
are high, establishing a potential role for phosphorylase
inhibitors in diabetes therapy.
Human liver glycogen phosphorylase (HLGP, a homo-
dimer of 846 residues per subunit) is allosterically regu-
lated by the binding of small molecule effectors and by
phosphorylation of Ser14, both of which induce conforma-
tional switching ([3,4] and references therein). Allosteric
effectors and phosphorylation alter enzyme activity by sta-
bilizing either the active or the inactive conformation. The
phosphorylated enzyme, HLGPa, may adopt both an ac-
tive or inactive conformation, the unphosphorylated en-
zyme, HLGPb, exhibits low activity but may be weakly
activated by AMP. The active conformation is stabilized
by phosphorylation of Ser14 and binding of AMP. The
inactive conformation is stabilized by dephosphorylation,
glucose, and the binding of heterocyclic compounds,
such as caffeine. Glucose binds at the catalytic site, caf-
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feine binds near to the catalytic site, and AMP binds to a
separate allosteric site. Glucose functions synergistically
with caffeine to inhibit phosphorylase [5].
Inhibitors of phosphorylase include glucose analogs (active
site) [6,7]; an AMP site inhibitor [8]; and hydroxylated
piperidines and pyrrolidines [9]. We recently reported
two series of indole-2-carboxamide inhibitors which have
oral activity in an animal model of type 2 diabetes [10,11].
The indole-2-carboxamides show caffeine-like synergy
with glucose, a desirable property which could minimize
the risk of hypoglycemia, a potentially severe side effect of
many antidiabetic agents. Here, we show that indole-2-
carboxamides bind to a novel, allosteric site on HLGPa
[12] and present the key features of the site which enabled
the design of a second class of inhibitor with nanomolar
af¢nity. During review of this manuscript, an independent
report of the crystal structure of a complex of another
member of this class of compounds (CP-320,626, [11])
with rabbit muscle glycogen phosphorylase b appeared
[13] showing that the site also exists in the inactive, un-
phosphorylated form of the rabbit muscle enzyme, and that
many of the interactions we now describe are conserved.
We have also observed this binding site in the crystal
structures of two other inhibitors of this class complexed
to the phosphorylated form of rabbit muscle phosphorylase
(VLR, personal communication).
Results and discussion
Discovery of the novel binding site
Initially, we thought that these glucose-sensitive inhibitors
bound to the caffeine site. Further analysis revealed that
they also exhibited synergism with caffeine [10], indicating
that a different locus was involved. To identify this site,
the crystal structure of HLGPa complexed with CP-
403,700, one of these compelling inhibitors, was solved
to 2.4 Aî resolution (see Figure 1 and Table 1).
The electron density of the bound inhibitor was located in
a difference map of a crystal of HLGPa grown in the
presence of a glucose analog, N-acetyl-L-D-glucopyranosyl-
amine (GlcNAc), and excess CP-403,700. GlcNAc was in-
cluded because it is a potent inhibitor of rabbit muscle
phosphorylase [8]. The compound binds to a new site on
the enzyme within the solvent cavity which forms part of
the dimer interface. Two molecules are identically bound,
very close to the axis of the molecular 2-fold symmetry
operator. Consequently, the two inhibitors are within 6 Aî
of each other and taken together, share one large, contin-
uous, binding site.
Description of the site
The binding site for each inhibitor is made up of residues
from both subunits and consists of two qualitatively differ-
ent environments (Figure 2). One environment is hydro-
phobic, formed almost exclusively from one subunit, and
houses the chloroindole moiety of the inhibitor; the other
binds the carboxamide, phenylalanine and azetidine moi-
eties, is both hydrophobic and polar, includes residues
from both subunits, and extends into a solvent-¢lled cavity.
The hydrophobic chloroindole pocket is formed from the
aliphatic part of the side chains of Arg60 and Lys191, and
the side chains of six other hydrophobic residues (Figure
2b). The chloroindole group is completely buried in the
complex. This includes 266 Aî 2 of hydrophobic surface area
which makes a large contribution to the binding energy.
Additionally, the indole nitrogen forms a hydrogen bond to
a backbone carbonyl and the guanidinium group of Arg60
appears to have a favorable electrostatic interaction with
the indole ring [14].
Figure 1. The new allosteric inhibitor site. HLGPa as a ribbon
diagram, one subunit in purple (helices) and pink (sheets) and the
other in green (helices) and blue (sheets). In CPK are AMP
(gray); Ser14-P (pink, red phosphates); PLP (pyridoxal phosphate,
the essential cofactor, in red); caffeine (green); GlcNAc (blue,
marks the glucose binding site); and CP-403,700 (carbon, pink;
nitrogen, blue; oxygen, red). Two-fold symmetry operator relating
the subunits located between the two molecules of CP-403,700,
orthogonal to the plane of the page. The binding sites for Ser14-P
and AMP are located close to each other but do not overlap. To
show all the binding sites in one image, a composite of three
crystal structures was made; AMP and residues 5^22 (including
Ser14-P) from the crystal structure of HLGPa complexed with
AMP (Rath, V.L. et al., Molecular Cell, in press); caffeine, from
crystals of HLGPa complexed with GlcNAc and CP-403,700
soaked in caffeine (manuscript in preparation); remainder from the
complex of HLGPa complexed with GlcNAc and CP-403,700
described herein.
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The second part of the inhibitor binding site is formed
from both subunits, includes more hydrogen bonds, and
is characterized by a less constrained ¢t with the com-
pound. Direct hydrogen bonds are formed to a backbone
carbonyl and to the side chain of Lys191. The phenylala-
nine side chain of the inhibitor forms van der Waals con-
tacts with a Pro, Phe and His but is less buried (84%) than
the chloroindole. The azetidine ring and its carboxylate are
solvent-exposed; only 57% of the total solvent accessible
surface area is buried in the complex. The carboxylate
makes only water-mediated hydrogen bonds to the en-
zyme.
The binding site of CP-403,700 in the crystal structure of
the active complex of HLGPa with AMP is masked by the
side chains of Arg60, Val64 and Lys191. This was deter-
mined by superimposing the CK carbons of one subunit
(residues 30^830) of the CP-403,700-inhibited complex on
the coordinates of the active complex of HLGPa with
AMP (Rath, V.L. et al., Molecular Cell, in press) and ex-
amining the interactions between the side chains of active
HLGPa/AMP and the compound. The results show that
the side chains of Arg60, Val64 and Lys191 of active
HLGPa lie within 0^1.2 Aî of the inhibitor and must
move to accommodate its binding. The required side chain
movements could not be predicted in the absence of CP-
403,700. Five other residues (38P, 40P, 53, 57 and 192)
make smaller adjustments to eliminate close contacts
with the inhibitor. Only one hydrogen bond (which is be-
tween the two subunits, Arg60:Thr38P) is disrupted on
inhibitor binding, and both residues have new hydrogen
bonding partners in the complex. Thr38P forms a hydrogen
bond to the indole nitrogen of the compound and the
guanidinium group of Arg60 forms a hydrogen bond to a
water molecule (in addition to stacking over the chloroin-
dole moiety).
Inhibitors are allosteric effectors
CP-403,700 functions as a classic allosteric inhibitor in that
it stabilizes the inactive conformation of the enzyme and
exhibits synergy with other inhibitors [15]. Over the range
of physiologic glucose concentrations (2.5^7.5 mM), the
inhibitory potency of the compound is increased 3-fold
(IC50 for CP-403,700 at 0 mM glucose, 0.145 WM; at 2.5
mM glucose, 0.054 WM; at 5.0 mM glucose, 0.028 WM; at
7.5 mM glucose, 0.0175 WM, see Materials and methods).
CP-403,700 increases the rate of dephosphorylation 2-fold,
as measured by the release of 32P from Ser14 [32P]HLGPa,
consistent with results reported for other allosteric inhibi-
tors of rabbit muscle glycogen phosphorylase a [5].
Design of a new class of inhibitors from the structure
We speculated that the most important structural compo-
nent of CP-403,700 for binding was the chloroindole car-
boxamide group. On seeing the closely bound inhibitors,
and aware of the potential in correctly joining two ligands
[16], we reasoned that joining two chloroindole groups to-
gether with an appropriate linker could give a new type of
inhibitor which would interact simultaneously with both
chloroindole binding pockets. After estimating the length
of a connector from the CP-403,700 X-ray structure, various
bis-indolecarboxamides were synthesized by coupling two
Table 1
Crystallographic data and re¢nement statistics.
HLGPa/1-GlcNAc/CP-403,700 HLGPa/1-GlcNAc/CP-526,423
Space group P31 (dimer in asymmetric unit) P31 (dimer in asymmetric unit)
Cell constants a = b = 124.63 Aî ; c = 124.06 Aî a = b = 123.31 Aî ; c = 122.32 Aî
K=L= 90.0³; Q= 120.0³ K= L= 90.0³; Q= 120.0³
Data collection statistics
Resolution 99.0^2.4 Aî 99.0^2.2 Aî
Unique re£ections 81,403 97,977
Redundancy 5^6 2^3
Resolution (last shell) 99.0^2.4 (2.49^2.4) 99.0^2.2 (2.28^2.2)
Chi2 1.04 (1.08) 1.07 (0.83)
Rmerge 0.071 (0.378) 0.074 (0.359)
I/error 19.1 (2.8) 13.6 (2.0)
Completeness (%) 99.8 (99.0) 97.8 (87.1)
Re¢nement statistics
Protein 23^249, 260^313, 326^830 22^249, 260^314, 324^830
Disordered 1^22, 250^259, 314^325, 831^846 1^22, 250^259, 315^323, 831^846
Ligands two molecules 1-GlcNAc two molecules 1-GlcNAc
(per dimer) two molecules CP-403,700 two molecules CP-526,423
two molecules MPD one molecule MPD
Water molecules 333 737
Resolution 99.0^2.4 Aî (2.55^2.4) 99.0^2.2 (2.34^2.2)
R 0.236 (0.283) 0.233 (0.307)
Rfree 0.280 (0.334) 0.264 (0.340)
r.m.s.d. bond lengths 0.007 Aî 0.006 Aî
r.m.s.d. bond angles 1.22³ 1.26³
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equivalents of 5-chloroindole-2-carboxylic acid with differ-
ent diamines, illustrated by CP-526,423 (Table 2). CP-
526,423 inhibits HLGPa with an IC50 of 6 nM, consistent
with productive, cooperative binding of both chloroindole
groups in their respective pockets.
To verify this hypothesis, CP-526,423 was co-crystallized
with HLGPa and the X-ray structure solved by molecular
replacement to 2.2 Aî resolution (Table 1). CP-526,423 is
well ordered in the electron density map, demonstrating
that a single molecule of CP-526,423 indeed spans the two
inhibitor sites (Figure 3). After superposition of the CK
carbons of residues 30^830 of the respective phosphorylase
monomers, the root mean square deviation (r.m.s.d.) of the
chloroindole moieties of CP-403,700 and CP-526,423 is
0.34 Aî .
The increase in potency derived from joining two ligands
together to give CP-526,423 is made apparent by compar-
ing the potency of CP-305,494 (Table 2). CP-305,494 is
expected to be able to make the same favorable interac-
tions as CP-526,423, except through two molecules, rather
than one, per HLGP homodimer. In effect, by linking two
molecules of CP-305,494 to make CP-526,423, the IC50 is
improved 2000-fold to 6 nM.
The solvent-¢lled gap between the two subunits of the
phosphorylase dimer may be necessary to allow the two
subunits to rotate (by 7‡) with respect to each other
when the enzyme is activated (Rath, V.L. et al., Molecular
Cell, in press). We have shown that a new allosteric bind-
ing site exists within this gap for the chloroindole carbox-
amide class of glycogen phosphorylase inhibitor. A repre-
sentative of this class reduces enzyme activity by
stabilizing the inactive conformation of the enzyme, like
other known allosteric inhibitors of phosphorylase. We
have determined the atomic resolution details of the inter-
actions between the compound and HLGPa which led to
the discovery of a new class of simpler, more potent inhib-
itors. These crystal structures provide the foundation for
further design of glycogen phosphorylase inhibitors for
treating diabetes.
Signi¢cance
Non-insulin-dependent (type 2) diabetes mellitus affects
Table 2
Structures and IC50 values for inhibitors.
aAverage of two experiments.
bSodium salt.
Figure 2. The binding site consists of two different protein
environments. (a) Solvent accessible surface. On the left, the site
is hydrophobic; on the right, the site is both hydrophobic and
polar, and open to solvent at the top, bottom and into the page
beyond the azetidine ring. The 2-fold symmetry operator relating
the subunits runs vertically in the plane of the page. CP-403,700
(carbon, pink; nitrogen, blue; oxygen, red; chlorine, purple) shown
with the solvent accessible surface area of the cavity (GRASP
[23]) in gray, regions of van der Waals contact shown in
turquoise. (b) Subunits colored blue and green as in Figure 1.
Hydrogen bonds shown are 2.6^3.2 Aî ; water molecules, red
spheres. Val40P, described in the text, is omitted for clarity.
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15 million people in the United States alone. The genetic
basis of this chronic metabolic disorder is poorly under-
stood but is characterized by defects in insulin secretion
and insulin action, leading to serious complications such as
nerve and kidney damage, blindness and heart disease. In
type 2 diabetics, the liver produces excess glucose and is a
major contributor to diabetic hyperglycemia. Recent data
suggest that tight blood glucose control is critical to pre-
vent or delay the onset of diabetic complications. The liver
produces glucose by gluconeogenesis (de novo synthesis of
glucose) and by glycogenolysis, the breakdown of glycogen
by liver phosphorylase. Although diabetes is not caused by
defects in liver phosphorylase, its inhibition may provide a
means of controlling glucose levels in circulating blood, an
effect which has been validated in an animal model of
diabetes.
We present two unreported compounds which bind to a
highly speci¢c, novel site on glycogen phosphorylase, an
enzyme which has been studied biochemically for over 60
years and crystallographically for 30 years. This is the ¢rst
description of the diabetes target, human liver phosphor-
ylase, complexed with an allosteric inhibitor. Compounds
which bind to this site are the most potent inhibitors of
liver phosphorylase identi¢ed to date and function, like
other known inhibitors, by stabilizing the inactive confor-
mation of the enzyme. Hence, these compounds are syn-
ergistic with active site inhibitors and promote dephos-
phorylation of the enzyme by the phosphatase, rendering
it inactive. The site involves unique structural elements
and reveals a new way the inactive conformation can be
stabilized from a different locus on the protein. The details
of the binding site have been exploited to design a second
generation, higher af¢nity inhibitor which also demon-
strates the concept of linking two ligands to create an ex-
ponentially more potent one.
Materials and methods
Figures were made using Midas Plus [17] except where noted.
Crystallization, data measurement, structure solution
Baculovirus-derived HLGPa was puri¢ed, crystallized with a 4-fold molar
excess of CP-403,700 sodium salt, and frozen as described [12]. The
synthesis of CP-403,700 has also been described [12]. Crystals of the
complex with CP-526,423 (synthesis to be described elsewhere) were
prepared in the same way. We were not able to obtain crystals with CP-
403,700 alone under these conditions, however little effort was made to
do so. Although we did obtain crystals of HLGPa complexed with the
glucose analog alone, they were less reproducible and took much lon-
ger to grow. The best crystals (largest, fastest growing) were obtained
when both CP-403,700 and the glucose analog, GlcNAc [18], were
present. Data from crystals of both complexes were measured at beam-
line X12C of Brookhaven National Laboratories. The complex with CP-
403,700 was solved by molecular replacement using HLGPa/AMP co-
ordinates (Rath, V.L. et al., Molecular Cell, in press); CP-526,423 was
solved using the CP-403,700 complex coordinates; solutions and re¢ne-
ment in X-PLOR [19] or CNS [20] using standard methods; models built
in O [21]. Coordinates have been deposited (CP-403,700 complex, PDB
entry 1EXV; CP-526,423 complex, PDB entry 1EMG).
Activity assays
HLGPa activity was measured as described [10], and the IC50 (concen-
tration at which the enzyme activity is 50% inhibited) values are the
average of duplicate determinations, performed in triplicate. Brie£y,
HLGPa (85 ng) activity was measured in the direction of glycogen syn-
thesis by the release of phosphate from glucose-1-phosphate at 22³C in
100 Wl of buffer containing 50 mM HEPES (pH 7.2), 100 mM KCl, 2.5
mM EGTA, 2.5 mM MgCl2, 0.5 mM glucose-1-phosphate and 1 mg/ml
glycogen. Phosphate was measured at 620 nm, 20 min after the addi-
tion of 150 Wl of 1 M HCl containing 10 mg/ml ammonium molybdate and
0.38 mg/ml malachite green. Test compounds were added to the assay
in 5 Wl of 14% dimethyl sulfoxide (DMSO).
Rate of dephosphorylation
HLGPb was converted to HLGPa by reaction with [32P]ATP and phos-
phorylase kinase [10]. [32P]GPa was incubated with CP-403,700 or CP-
526,423 (1 WM) or DMSO (control), in the presence or absence of 40
mM glucose. Protein phosphatase 1 (PP1) was added to initiate de-
phosphorylation, and at each time point, an aliquot removed for SDS^
PAGE determination of the remaining [32P]HLGPa. The HLGP bands
were cut from dried gels and [32P]HLGPa quantitated by scintillation
counting (modi¢cation of [22]). Results expressed as % remaining
[32P]HLGPa relative to the 0 min (pre-PP1 addition) time point. The
experiment was independently performed three times with results given
as the mean of duplicate determinations from a representative experi-
ment.
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Figure 3. The structure of the HLGPa complexed with CP-
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